Cervical cancer is the second most common cause of cancer deaths in women worldwide.

RAIDs is a multidisciplinary co-operation between academic clinical centers, Small medium enterprises and translational research platforms. It combines Next Generation Sequencing (NGS) and Reverse Phase Protein array (RPPA) in a large patient population prior to standard therapy.
In addition, high throughput screening techniques have been performed in Cervical Cancer cell lines, allowing to identify new drugs of relevance for advanced stage multi resistant Cervical Cancer. These molecules are to be validated in preclinical mouse models. Ongoing studies will assess in vitro efficacy of drug targeting according to molecular phenotypes.

At the core of the RAIDs project is BioRAID, a clinical trial including a substantial biobanking effort for molecular profiling with high standards of quality control of biological and clinical data. To our knowledge, BioRAIDs is one of the first prospective trials of this type aiming to identify predictive biomarkers for treatment response in cervical cancer patients. RAIDs results will be priceless to identify a set of stratification criteria that will help in the near future to better orient patient to a more personalized treatment. Main clinical trial support structures are based at the promoter site at Institut Curie with sponsorship delegations to Hannover (HCTC), ECRIN and NKI, Amsterdam. Genetic mutations (SeqOmics, Hungary), proteomic alteration (Translational platform Institut Curie) and their influence on the tumor microenvironment (NKI) of cervical cancers from 7 EU countries are being analyzed. Lacking harmonization in regulatory requirements across Europe and variable levels of experience with biobanking and clinical trial conduct had been a major challenge to the implementation of BioRAIDs study, which is actively including patients today.


RAIDs project include a first-in-man DNA Vaccine trial, currently ongoing at NKI Amsterdam accruing well. AmBTU is responsible for the production of the clinical grade plasmid DNA.

The project is expected to provide new tools for early diagnosis and targeted treatments exploited by SMEs and to accelerate innovation of Cervical Cancer therapy and improve quality of life.